@inproceedings{inproceedings, title  = {{Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group}},

 url = {{}},

 year = {{2013}},

 month = {{9}},

 author = {{Wiechno P and Helle SI and Logue J and Nilsson S and Sartor O and Coleman RE and Kliment J and Fang F and Parker C}},

 volume = {{49}},

 journal = {{EUROPEAN JOURNAL OF CANCER}},

 pages = {{S690-S691}},

 note = {{Accessed on 2025/10/10}}}